The long-term potential of ultrasound contrast agents may be great, but ultrasound practitioners appear to be taking a measured approach to the technology, if the third-quarter financial results of Molecular Biosystems are any indication. The San Diego
The long-term potential of ultrasound contrast agents may be great, but ultrasound practitioners appear to be taking a measured approach to the technology, if the third-quarter financial results of Molecular Biosystems are any indication. The San Diego ultrasound contrast developer this month released financial results for the quarter (end-September) that show only a slight increase in sales of its Optison contrast agent.
For the period, MBI had product and royalty revenues of $1.41 million, most of which were Optison sales. This compares with product and royalty revenues of $1.37 million in the second quarter of 1998. MBI and marketing partner Mallinckrodt of St. Louis launched Optison in January.
MBI recorded total third-quarter revenues of $2.7 million, compared with sales of $1.4 million in the third quarter of 1997. The company posted a net loss of $7.1 million in the most recent period, compared with a loss of $4.6 million in the same period a year ago.
MBI president and CEO Bobba Venkatadri acknowledged that sales of Optison are growing at a modest pace, but he said the company remains confident in the agents long-term potential. Shares of MBI fell 13% to close at $3.38 on Oct. 21, the day the news was announced.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.